Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial

INTRODUCTION: BAY 81‐8973 (Kovaltry(®)) is a full‐length, unmodified recombinant human factor VIII approved in China for prophylaxis and on‐demand treatment in patients with haemophilia A. Limited access to FVIII prophylaxis in China has historically led to this population being undertreated. This s...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Haemophilia
Main Authors: Yang, Renchi, Sun, Jing, Zhao, Yongqiang, Wang, Xuefeng, Wu, Depei, Tseneklidou‐Stoeter, Despina, Wu, Junde, Church, Nikki
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
ORIGINAL ARTICLES
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6850381/
https://ncbi.nlm.nih.gov/pubmed/30993836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13751
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki